ARMY AL&T
The underlying goal has always been to deliver those vaccines into the arms of an anxiously waiting public.
supported a 20 percent increase in the number of U.S. vaccina- tions, providing over 31 percent of the U.S. government’s LDS syringe procurement goal.
PACK OUT
Defense Logistics Agency supply technician Brandon Gerber packs Moderna vaccine ancillary kits—which typically contain needles, syringes, vaccine cards and other essential items for 100 vaccines—to be shipped overseas. (Photo by Nutan Chada, Defense Logistics Agency)
ACCELERATING VACCINE ROLLOUT To support an accelerated vaccine rollout of needle and syringe deliveries for ancillary kits, the team turned to the U.S. Transpor- tation Command (USTRANSCOM), DOD’s premier provider of full-spectrum global mobility solutions. Te team modified its transportation requirements across all contracts to acceler- ate delivery and provide 35 percent more product over the first three months, in support of the emergency use authorization and advanced distribution of the COVID-19 vaccines. While commercial air transportation availability was critically short because of the pandemic, JPM CBRN Medical’s cooperative efforts with USTRANSCOM led to a successful international airlift of approximately 200 million needles and syringes.
Subsequent to the initial COVID-19 vaccination campaign, Mountney and the team worked with counterparts in HHS and supported the U.S. government acquisition strategy for expanded needle and syringe procurements to support four follow-on missions:
and export activities, and to synchronize allocation of products across distribution sites for ancillary kit building and nationwide distribution. Ancillary kits typically contain needles, syringes, alcohol pads, vaccination cards and protective equipment for medical professionals to support approximately 100 vaccinations per kit.
As vaccine candidates emerged and raced toward U.S. Food and Drug Administration (FDA) emergency use authorization, the team proactively pivoted to focus on and prioritize acquiring the low dead space (LDS) syringes that were necessary to draw the maximum number of doses per vial. Tese syringes were field tested to support drawing six doses from the Pfizer vaccine and
• COVID-19 vaccination humanitarian assistance. • Annual COVID-19 booster shots. • Support for vaccinations against new COVID variants. • Replenishment and expansion of the strategic national stock- pile inventory.
Together, they helped to develop a multifaceted strategy that leveraged inventory surplus with carefully planned potential new procurement actions in order to maximize product deliv- eries to meet requirements, while reducing the risk of medical supply chain disruption. Mountney briefed HHS and DOD senior leaders, as well as the White House COVID-19 supply chain coordinator, on the current status of needles and syringes
https://asc.ar my.mil 45
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92
